



21 March 2018

(18-1717)

Page: 1/1

Committee on Technical Barriers to Trade

Original: English

### NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

<b>1. Notifying Member:</b> UNITED STATES OF AMERICA <b>If applicable, name of local government involved (Article 3.2 and 7.2):</b>
<b>2. Agency responsible:</b> Food and Drug Administration (FDA), Health and Human Services (HHS) [1372] <b>Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:</b>  Please submit comments to: USA WTO TBT Enquiry Point Email: <a href="mailto:usatbtep@nist.gov">usatbtep@nist.gov</a>
<b>3. Notified under Article 2.9.2 [ ], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other: [X]</b>
<b>4. Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):</b> Extracorporeal shock wave device; Medical equipment (ICS 11.040).
<b>5. Title, number of pages and language(s) of the notified document:</b> Medical Devices; General and Plastic Surgery Devices; Classification of the Extracorporeal Shock Wave Device for Treatment of Chronic Wounds (3 page(s), in English)
<b>6. Description of content:</b> The Food and Drug Administration (FDA or we) is classifying the extracorporeal shock wave device for treatment of chronic wounds into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the extracorporeal shock wave device for treatment of chronic wounds' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
<b>7. Objective and rationale, including the nature of urgent problems where applicable:</b> Protection of human health or safety
<b>8. Relevant documents:</b> 83 Federal Register (FR) 9698, 7 March 2018; Title 21 Code of Federal Regulations (CFR) Part 878.
<b>9. Proposed date of adoption:</b> 28 December 2017 <b>Proposed date of entry into force:</b> 7 March 2018
<b>10. Final date for comments:</b> None
<b>11. Texts available from: National enquiry point [ ] or address, telephone and fax numbers and email and website addresses, if available, of other body:</b> <a href="https://members.wto.org/crnattachments/2018/TBT/USA/18_1583_00_e.pdf">https://members.wto.org/crnattachments/2018/TBT/USA/18_1583_00_e.pdf</a>